Vaxcyte (PCVX) Cash from Investing Activities (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Cash from Investing Activities data on file, last reported at -$233.4 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$233.4 million, down 289.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $80.6 million (up 105.63% YoY), and the FY2025 annual result was $437.4 million, up 121.81% from the prior year.
• Cash from Investing Activities fell to -$233.4 million in Q1 2026 per PCVX's latest filing, from $115.1 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $123.3 million in Q1 2025 and troughed at -$917.0 million in Q3 2024.
• A 5-year average of -$147.1 million and a median of -$13.9 million in 2023 frame the typical range for Cash from Investing Activities.
• On a YoY basis, Cash from Investing Activities climbed as much as 287.91% in 2022 and fell as far as 43943.9% in 2022.
• A 5-year view of Cash from Investing Activities shows it stood at -$36.0 million in 2022, then surged by 61.27% to -$13.9 million in 2023, then plunged by 3900.92% to -$557.2 million in 2024, then surged by 120.66% to $115.1 million in 2025, then tumbled by 302.74% to -$233.4 million in 2026.
• Business Quant data shows PCVX's Cash from Investing Activities at -$233.4 million in Q1 2026, $115.1 million in Q4 2025, and $121.2 million in Q3 2025.